Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

Bone Marrow Transplantation volume 37, pages 825–829 (2006)Cite this article

Abstract

Although autologous stem cell transplant is an effective therapy for patients with multiple myeloma and extends progression-free survival (PFS) and overall survival (OS), patients show a continued pattern of recurrent disease. Twenty-nine patients were enrolled in a phase II study investigating the tolerability and efficacy of maintenance thalidomide following single autologous peripheral blood stem cell transplant. Six to eight weeks after transplant, patients were started on maintenance thalidomide at 50 mg a day. The dose was gradually escalated to a target dose of 400 mg a day and continued until disease progression or 6 months after achieving complete remission (CR) for a maximum total duration of 18 months. At 6 months, 13 patients (45%) achieved CR or near complete remission (positive immunofixation without any evidence of disease). The estimated 2-year OS was 83% and PFS was 49%. Median tolerated dose of thalidomide was 200 mg a day. In conclusion, thalidomide as maintenance therapy is feasible and may improve outcome after single autologous stem cell transplant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results. Br J Haematol 1998; 102: 495–502.

    Article  CAS  Google Scholar 

  2. Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950.

    CAS  Google Scholar 

  3. Davis F, Raje N, Hideshima T, Lentzsch S, Yong G, Tai Y et al. Thalidomide and immuno modulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

    Article  Google Scholar 

  4. Gupta D, Treon SP, Shima Y, Hideshma T, Podark K, Tai Y et al. Adherence of multiple myeloma cells to bone marrow stromal cell upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961.

    Article  CAS  Google Scholar 

  5. Weber D, Rankin K, Gavino M, Delsalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  Google Scholar 

  6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 34: 1565–1571.

    Article  Google Scholar 

  7. Mahoney D, Molina A, Sahebi F, Stockerl-Goldstein K, Sandmaier B, Bensinger W et al. Allografting with non-myleloablative. Conditioning following cyotoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    Article  Google Scholar 

  8. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplant: myeloma subcommittee of the EBMT. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  Google Scholar 

  9. Stewart K, Chen C, Howson-Jan K, White D, Roy J, Kovacs M et al. Results of multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 24: 8170–8176.

    Article  Google Scholar 

  10. Scarpace S, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A et al. Arterial thrombosis in four patients treated with thalidomide. Leukemia and Lymphoma 2005; 46: 239–242.

    Article  Google Scholar 

  11. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al. Thalidomide and deep venous thrombosis in multiple myeloma:risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35.

    Article  CAS  Google Scholar 

  12. Barlogie B, Desikan R, Eddelmon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494.

    Article  CAS  Google Scholar 

  13. Neben K, Moehler T, Benner A, Egere G, Ho A, Goldschmidt H et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382.

    CAS  Google Scholar 

  14. Palumbo A, Bertola A, Falco P, Cavallo F, Giaccone L, Bringhen S et al. Efficacy of low dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318–324.

    Article  CAS  Google Scholar 

  15. Durie BG . Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 2002; 29 (6 Suppl): 34–38.

    Article  CAS  Google Scholar 

  16. Alexanian R, Weber D, Giralt S, Delasalle KL . Consolidation therapy of multiple myeloma with thalidomide–dexamethasone after intensive therapy. Ann Oncol 2002; 13: 1116–1119.

    Article  CAS  Google Scholar 

  17. Attal M, Harousseau HL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma. First analysis of prospective randomized study of IFM99-02. Blood 2004; 10 (abstract 535).

  18. Tricot G, Rasmussen E, Anaissie E, Van Rhee F, Zangari M, Holling K et al. Total therapy 2 (TT 2) for multiple myeloma: thalidomide effects superior complete response and event-free survival; similar overall survival linked to shorter post relapse survival. Blood 2005; 106 (abstract 423).

  19. Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K, Johnson RL . Thalidomide maintenance following high dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Blood 2005; 106 (abstract 641).

Download references

Author information

Author notes

  1. F Sahebi, R Spielberger, N M Kogut and P M Falk: Southern California Kaiser Permanente Medical Group.

Authors and Affiliations

  1. Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    F Sahebi, R Spielberger, N M Kogut, H Fung, P M Falk, P Parker, A Krishnan, R Rodriguez, R Nakamura, A Nademanee, L Popplewell, P Frankel, C Ruel, R Tin, P Ilieva, S J Forman & G Somlo

Authors
  1. F Sahebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Spielberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N M Kogut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P M Falk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Krishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Nademanee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Popplewell
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Frankel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Ruel
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Tin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P Ilieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S J Forman
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. G Somlo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Sahebi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahebi, F., Spielberger, R., Kogut, N. et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 37, 825–829 (2006). https://doi.org/10.1038/sj.bmt.1705339

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705339

Keywords

This article is cited by

Search

Advanced search

Quick links